Table 1.
Baseline demographics and clinical characteristics of patients enrolled in ABC‐08
| Characteristic | NUC‐1031 a 625 mg/m2 (n = 15) | NUC‐1031 a 725 mg/m2 (n = 6) |
|---|---|---|
| Age, median (range), years | 61 (55–78) | 59.5 (47–71) |
| Gender | ||
| Male | 10 | 3 |
| Female | 5 | 3 |
| ECOG PS | ||
| 0 | 4 | 3 |
| 1 | 11 | 3 |
| Primary tumor site | ||
| Intrahepatic | 5 | 0 |
| Hilar | 3 | 4 |
| Distal bile duct | 3 | 2 |
| Gallbladder cancer | 2 | 0 |
| Ampulla of Vater carcinoma | 2 | 0 |
| Disease status | ||
| Locally advanced | 3 | 1 |
| Metastatic | 12 | 5 |
| Recurrent disease | ||
| No | 11 | 2 |
| Yes | 4 | 4 |
a
In combination with cisplatin 25 mg/m2 on days 1 and 8 (21‐day schedule).
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.